This site is intended for healthcare professionals

Phase III FIGARO-DKD study of BAY 94 8862 meets primary endpoint in patients with chronic kidney disease and type 2 diabetes.- Bayer HealthCare

Read time: 1 mins
Last updated:28th Jun 2021
Published:11th May 2021
Bayer’s Phase III cardiovascular outcomes study FIGARO-DKD, evaluating the efficacy and safety of the investigational drug BAY 94 8862 (finerenone) versus placebo when added to standard of care in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) has met its primary endpoint.
Condition: Diabetes Type 2 and Kidney Disease
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest